• Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes
• The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome
• The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021
• It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the potential of DehydraTECH-CBD for the treatment of hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. The company’s patented DehydraTECH(TM) drug delivery platform technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients. They recently completed its diabetes animal model study DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes. The study produced at least three positive outcomes in what Lexaria’s management described as “encouraging,” further indicating many prospective benefits worthy of further investigation together down the line (https://ibn.fm/7ZZyw).

The study, which involved 32 male Zucker (“ZDF”) rats- 24 obese and eight lean, saw the administration of Lexaria’s “DehydraTECH-CBD 2.0” formulations at either 30 mg/Kg or 100 mg/Kg of body weight. Following initial positive early responses witnessed, the study, which was to last for four weeks, was extended to eight, with outcomes including weight loss in obese diabetic-conditioned animals, to improved triglyceride and cholesterol levels.

Across all three parameters, only the lower dose of DehydraTECH-CBD achieved the most optimum outcome, with higher doses showing no significant difference. With activity levels, for instance, lower DehydraTECH-CBD doses resulted in a statistically significant improvement in locomotor activity compared to the untreated obese control rats, with no significant difference accordingly evidenced at the higher dose. Furthermore, a lower dose of 30 mg/Kg also outperformed the higher dose of 100 mg/Kg with reductions in triglyceride levels from day 35 onwards compared to the obese animals not dosed with DehydraTECH-CBD.

No severe health concerns were observed during dosing in the animals that received DehydraTECH-CBD. Lexaria’s management was keen to express its pleasure that relatively low doses of DehydraTECH-CBD seemed to support tangible improvements in the day-to-day health of the lab animals. This showed how essential the findings are for many other prospective benefits worthy of further investigation, perhaps with other drugs that further help control glucose levels directly.

Lexaria’s unique and powerful drug delivery technology, DehydraTECH, has proven to enhance the performance of several categories of fat-soluble molecules and drugs across oral and/or topical product formats. As a result, it is an additional step easily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical products. This feature has been applied in antiviral drugs, cannabinoids, oral nicotine, PDE5 inhibitors, and more. The technology’s potential has also opened up Lexaria’s licensing opportunities, particularly given the technology’s suitability for use with a growing range of consumer products such as registered drugs, nutraceuticals, oral suspensions, capsules, pills and tablets (https://ibn.fm/XEet7).

The success of the DIAB-A22-1 animal model study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021 (https://ibn.fm/Sh4FG). It also points to the technology’s effectiveness, particularly following the success of Lexaria’s most ambitious human clinical study, HYPER-H21-4, demonstrating the potential of DehydraTECH-CBD for treating hypertension. This success also aligns with the company’s objective of delivering financial rewards to its shareholders, all while proving the validity of its technology.

“it is my goal for 2023 to make Lexaria Bioscience one of the top drug delivery performers in the biotech/pharmaceutical world as we continue to prove the validity of our technology, and really begin our efforts to deliver financial rewards to you, our owners,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/5RYiA).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]